Executive Summary: Clinical Practice Guideline of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD) in China

Abstract

Chronic kidney disease (CKD) is a global health concern. The prevalence of CKD in Chinese adults is over 10%. Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the complications of CKD, which may cause many serious adverse outcomes such as disability and death in CKD patients. In recent years, a series of guidelines for the diagnosis and treatment of CKD-MBD have been developed by several international organizations for kidney disease. In 2013, the working group developed the <i>Guidance for Diagnosis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder</i>, which greatly promoted clinical management and researches of CKD-MBD in China. In the past five years, Chinese clinicians have been deepening their understanding and standardized management of CKD-MBD and implemented a large number of clinical and basic researches on CKD-MBD. In combination with international research results, the working group updated the guidelines. This guideline includes five chapters: introduction and definition of CKD-MBD; diagnosis of CKD-MBD; prevention and treatment of CKD-MBD; prevention and treatment of osteoporosis in patients with CKD; and evaluation and treatment of CKD-MBD in kidney transplant recipients; and five appendixes. In this summary, we highlight the main recommendations and suggestions of the guideline.